INS and Disorder of lipid metabolism: To determine whether miR-29 represents a candidate therapeutic target for lipid metabolic disorders, future work must carefully assess the effects of long-term inhibition of miR-29 on not only hepatic and circulating lipid profiles, but also additional phenotypes such as hepatic proliferative capacity, inflammation, fibrosis, and insulin sensitivity.